Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth

Cancer Letters

Volumn 368, Issue 1, 2015, Pages 79-87

  Hover, Laura D ^a   Young, Christian D ^a   Bhola, Neil E ^a   Wilson, Andrew J ^a,b   Khabele, Dineo ^a,b   Hong, Charles C ^c,d   Moses, Harold L ^d   Owens, Philip ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BMP; BMPR1a; DMH1; Ovarian cancer; Platinum resistance

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; CISPLATIN; DMH 1; PLATINUM COMPLEX; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DMH1 COMPOUND; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CHEMOSENSITIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; OVARY TUMOR; PATHOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; CELL PROLIFERATION; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PYRAZOLES; QUINOLINES; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84940467157     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.032     Document Type: Article

References (73)

1. Kurman R.J., Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol 2010, 34:433-443.
2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin 2015, 65:5-29.
3. SEER Stat Fact Sheets: Ovary Cancer (1992-2012) 2015, in NCI.
4. Peng J., Yoshioka Y., Mandai M., Matsumura N., Baba T., Yamaguchi K., et al. The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-a potential therapeutic target. Mol. Carcinog 2015.
5. Miyazono K., Kamiya Y., Morikawa M. Bone morphogenetic protein receptors and signal transduction. J. Biochem 2010, 147:35-51.
6. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241.
7. Singh A., Morris R.J. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 2010, 21:299-313.
8. Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., Petersen G.M., et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat. Genet 2001, 28:184-187.
9. Kobielak K., Pasolli H.A., Alonso L., Polak L., Fuchs E. Defining BMP functions in the hair follicle by conditional ablation of BMP receptor IA. J. Cell Biol 2003, 163:609-623.
10. Andl T., Ahn K., Kairo A., Chu E.Y., Wine-Lee L., Reddy S.T., et al. Epithelial Bmpr1a regulates differentiation and proliferation in postnatal hair follicles and is essential for tooth development. Development 2004, 131:2257-2268.
11. Ming Kwan K., Li A.G., Wang X.J., Wurst W., Behringer R.R. Essential roles of BMPR-IA signaling in differentiation and growth of hair follicles and in skin tumorigenesis. Genesis 2004, 39:10-25.
12. Yuhki M., Yamada M., Kawano M., Iwasato T., Itohara S., Yoshida H., et al. BMPR1A signaling is necessary for hair follicle cycling and hair shaft differentiation in mice. Development 2004, 131:1825-1833.
13. Owens P., Pickup M.W., Novitskiy S.V., Chytil A., Gorska A.E., Aakre M.E., et al. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2814-2819.
14. Soda H., Raymond E., Sharma S., Lawrence R., Cerna C., Gomez L., et al. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs 1998, 9:327-331.
15. Ghosh-Choudhury N., Ghosh-Choudhury G., Celeste A., Ghosh P.M., Moyer M., Abboud S.L., et al. Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim. Biophys. Acta 2000, 1497:186-196.
16. Ghosh-Choudhury N., Woodruff K., Qi W., Celeste A., Abboud S.L., Ghosh Choudhury G. Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem. Biophys. Res. Commun 2000, 272:705-711.
17. Pouliot F., Labrie C. Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J. Endocrinol 2002, 172:187-198.
18. Kulessa H., Turk G., Hogan B.L. Inhibition of Bmp signaling affects growth and differentiation in the anagen hair follicle. EMBO J. 2000, 19:6664-6674.
19. Gao H., Chakraborty G., Lee-Lim A.P., Mo Q., Decker M., Vonica A., et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012, 150:764-779.
20. Ketolainen J.M., Alarmo E.L., Tuominen V.J., Kallioniemi A. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res. Treat 2010, 124:377-386.
21. Katsuno Y., Hanyu A., Kanda H., Ishikawa Y., Akiyama F., Iwase T., et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 2008, 27:6322-6333.
22. Morrissey C., Brown L.G., Pitts T.E., Vessella R.L., Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 2010, 12:192-205.
23. Ehata S., Yokoyama Y., Takahashi K., Miyazono K. Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde?. Pathol. Int 2013, 63:287-296.
24. Alarmo E.L., Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocr. Relat. Cancer 2010, 17:R123-R139.
25. Shepherd T.G., Mujoomdar M.L., Nachtigal M.W. Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion. J. Ovarian Res 2010, 3:5.
26. Edson M.A., Nalam R.L., Clementi C., Franco H.L., Demayo F.J., Lyons K.M., et al. Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol. Endocrinol 2010, 24:1251-1266.
27. McLean K., Gong Y., Choi Y., Deng N., Yang K., Bai S., et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J. Clin. Invest 2011, 121:3206-3219.
28. Ma W., Ma J., Xu J., Qiao C., Branscum A., Cardenas A., et al. Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment. Cell Cycle 2013, 12:88-97.
29. Herrera B., van Dinther M., Ten Dijke P., Inman G.J. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res 2009, 69:9254-9262.
30. Tsai C.L., Tsai C.N., Lin C.Y., Chen H.W., Lee Y.S., Chao A., et al. Secreted stress-induced phosphoprotein 1 activates the ALK2-SMAD signaling pathways and promotes cell proliferation of ovarian cancer cells. Cell Rep 2012, 2:283-293.
31. Peart T.M., Correa R.J., Valdes Y.R., Dimattia G.E., Shepherd T.G. BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation. Clin. Exp. Metastasis 2012, 29:293-313.
32. Moll F., Millet C., Noel D., Orsetti B., Bardin A., Katsaros D., et al. Chordin is underexpressed in ovarian tumors and reduces tumor cell motility. FASEB J. 2006, 20:240-250.
33. Theriault B.L., Shepherd T.G., Mujoomdar M.L., Nachtigal M.W. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 2007, 28:1153-1162.
34. Shepherd T.G., Theriault B.L., Nachtigal M.W. Autocrine BMP4 signalling regulates ID3 proto-oncogene expression in human ovarian cancer cells. Gene 2008, 414:95-105.
35. Wilson A.J., Liu A.Y., Roland J., Adebayo O.B., Fletcher S.A., Slaughter J.C., et al. TR3 modulates platinum resistance in ovarian cancer. Cancer Res 2013, 73:4758-4769.
36. Owens P., Engelking E., Han G., Haeger S.M., Wang X.J. Epidermal Smad4 deletion results in aberrant wound healing. Am. J. Pathol 2010, 176:122-133.
37. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
38. Gyorffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q., et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat 2010, 123:725-731.
39. Burleson K.M., Boente M.P., Pambuccian S.E., Skubitz A.P. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J. Transl. Med 2006, 4:6.
40. Shield K., Ackland M.L., Ahmed N., Rice G.E. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol. Oncol 2009, 113:143-148.
41. Liao J., Qian F., Tchabo N., Mhawech-Fauceglia P., Beck A., Qian Z., et al. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS ONE 2014, 9.
42. Liscovitch M., Ravid D. A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 2007, 245:350-352.
43. Li J., Wood W.H., Becker K.G., Weeraratna A.T., Morin P.J. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 2007, 26:2860-2872.
44. Januchowski R., Zawierucha P., Andrzejewska M., Rucinski M., Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed. Pharmacother 2013, 67:240-245.
45. Sherman-Baust C.A., Becker K.G., Wood Iii W.H., Zhang Y., Morin P.J. Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J. Ovarian Res 2011, 4:1757-2215.
46. Shepherd T.G., Nachtigal M.W. Identification of a putative autocrine bone morphogenetic protein-signaling pathway in human ovarian surface epithelium and ovarian cancer cells. Endocrinology 2003, 144:3306-3314.
47. Le Page C., Ouellet V., Madore J., Ren F., Hudson T.J., Tonin P.N., et al. Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br. J. Cancer 2006, 94:436-445.
48. Le Page C., Puiffe M.L., Meunier L., Zietarska M., de Ladurantaye M., Tonin P.N., et al. BMP-2 signaling in ovarian cancer and its association with poor prognosis. J. Ovarian Res 2009, 2:4.
49. Ma Y., Ma L., Guo Q., Zhang S. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. J. Exp. Clin. Cancer Res 2010, 29:85.
50. Laatio L., Myllynen P., Serpi R., Rysa J., Ilves M., Lappi-Blanco E., et al. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells. Tumour Biol 2011, 32:985-995.
51. Hong C.C., Yu P.B. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev 2009, 20:409-418.
52. Hao J., Ho J.N., Lewis J.A., Karim K.A., Daniels R.N., Gentry P.R., et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem. Biol 2010, 5:245-253.
53. Ao A., Hao J., Hopkins C.R., Hong C.C. DMH1, a novel BMP small molecule inhibitor, increases cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells. PLoS ONE 2012, 7:e41627.
54. Neely M.D., Litt M.J., Tidball A.M., Li G.G., Aboud A.A., Hopkins C.R., et al. DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem. Neurosci 2012, 3:482-491.
55. Engers D.W., Frist A.Y., Lindsley C.W., Hong C.C., Hopkins C.R. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg. Med. Chem. Lett 2013, 23:3248-3252.
56. Langenfeld E., Hong C.C., Lanke G., Langenfeld J. Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines. PLoS ONE 2013, 8:e61256.
57. Nishimori H., Ehata S., Suzuki H.I., Katsuno Y., Miyazono K. Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. J. Biol. Chem 2012, 287:20037-20046.
58. Balboni A.L., Hutchinson J.A., DeCastro A.J., Cherukuri P., Liby K., Sporn M.B., et al. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res 2013, 73:1020-1030.
59. Robson N.C., Hidalgo L., McAlpine T., Wei H., Martinez V.G., Entrena A., et al. Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling. Cancer Res 2014, 74:5019-5031.
60. Owens P., Pickup M.W., Novitskiy S.V., Giltnane J.M., Gorska A.E., Hopkins C.R., et al. Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene 2014.
61. Miow Q.H., Tan T.Z., Ye J., Lau J.A., Yokomizo T., Thiery J.P., et al. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 2014.
62. Davis A., Tinker A.V., Friedlander M. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?. Gynecol. Oncol 2014, 133:624-631.
63. Fraser M., Leung B., Jahani-Asl A., Yan X., Thompson W.E., Tsang B.K. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod. Biol. Endocrinol 2003, 1:66.
64. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
65. Ali A.Y., Farrand L., Kim J.Y., Byun S., Suh J.Y., Lee H.J., et al. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann. N. Y. Acad. Sci 2012, 1271:58-67.
66. Bowden N.A. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?. Cancer Lett 2014, 346:163-171.
67. Pavan S., Olivero M., Cora D., Di Renzo M.F. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. Eur. J. Cancer 2013, 49:964-973.
68. Helleman J., Jansen M.P., Burger C., van der Burg M.E., Berns E.M. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. Int. J. Biochem. Cell Biol 2010, 42:25-30.
69. Marchini S., Fruscio R., Clivio L., Beltrame L., Porcu L., Fuso Nerini I., et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer 2013, 49:520-530.
70. Baribeau S., Chaudhry P., Parent S., Asselin E. Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS ONE 2014, 9:e86987.
71. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
72. Samavarchi-Tehrani P., Golipour A., David L., Sung H.K., Beyer T.A., Datti A., et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010, 7:64-77.
73. Buijs J.T., Henriquez N.V., van Overveld P.G., van der Horst G., ten Dijke P., van der Pluijm G. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin. Exp. Metastasis 2007, 24:609-617.